Merck: 4-week hepatitis C treatment too short By: CNBC.com News November 10, 2014 at 18:52 PM EST Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful. Read More >> Related Stocks: Gilead Sciences Merck & Co